Schizophrenia and weight management: a systematic review of interventions to control weight

Objective: Weight gain is a frequent side effect of antipsychotic medication which has serious implications for a patient's health and well being. This study systematically reviews the literature on the effectiveness of interventions designed to control weight gain in schizophrenia.

[1]  J. Shaw,et al.  The prevention of type 2 diabetes--lifestyle change or pharmacotherapy? A challenge for the 21st century. , 2003, Diabetes research and clinical practice.

[2]  D. Allison,et al.  Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial , 2003, European Neuropsychopharmacology.

[3]  C. Fuchs,et al.  Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. , 2003, The American journal of psychiatry.

[4]  S. Biddle,et al.  Mental health nursing and the promotion of physical activity. , 2002, Journal of psychiatric and mental health nursing.

[5]  G. Chouinard,et al.  Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. , 2002, The Journal of clinical psychiatry.

[6]  F. Benazzi.  High frequency of residual depressive symptoms in bipolar II disorder: the need for a better treatment. , 2002, The Journal of clinical psychiatry.

[7]  Jacqueline A Pugh,et al.  Management of overweight and obese adults , 2002, BMJ : British Medical Journal.

[8]  P. Houck,et al.  Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. , 2002, Clinical therapeutics.

[9]  L. Kopala,et al.  Extreme weight gain in a youth with schizophrenia: risk/benefit considerations , 2002, Schizophrenia Research.

[10]  U. Werneke,et al.  Options for pharmacological management of obesity in patients treated with atypical antipsychotics , 2002, International clinical psychopharmacology.

[11]  C. Fuchs,et al.  Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. , 2002, The American journal of psychiatry.

[12]  D. Allison,et al.  Changes in body mass index for individuals with and without schizophrenia, 1987–1996 , 2002, Schizophrenia Research.

[13]  M. Fuller,et al.  Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. , 2002, The Journal of clinical psychiatry.

[14]  B. Barton,et al.  Metformin for weight loss in pediatric patients taking psychotropic drugs. , 2002, The American journal of psychiatry.

[15]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[16]  W. Poston,et al.  Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials , 2002, International Journal of Obesity.

[17]  E. Melanson,et al.  American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. , 2001, Medicine and science in sports and exercise.

[18]  D. Osborn,et al.  The poor physical health of people with mental illness. , 2001, The Western journal of medicine.

[19]  Evins,et al.  A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. , 2001, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[20]  R. Buchanan,et al.  A program for treating olanzapine-related weight gain. , 2001, Psychiatric services.

[21]  D. Umbricht,et al.  Cognitive behavior therapy for weight gain. , 2001, The American journal of psychiatry.

[22]  D. Allison,et al.  Antipsychotic-induced weight gain: a review of the literature. , 2001, The Journal of clinical psychiatry.

[23]  W. Fleischhacker,et al.  The clinical implications of weight gain in schizophrenia. , 2001, The Journal of clinical psychiatry.

[24]  M. Joffres,et al.  A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as indicators of cardiovascular risk factors. The Canadian Heart Health Surveys , 2001, International Journal of Obesity.

[25]  D. Allison,et al.  Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate , 2001, Psychiatry Research.

[26]  M. Floris,et al.  Effect of amantadine on weight gain during olanzapine treatment , 2001, European Neuropsychopharmacology.

[27]  J. Després,et al.  Treatment of obesity: need to focus on high risk abdominally obese patients , 2001, BMJ : British Medical Journal.

[28]  M. Phelan,et al.  Physical health of people with severe mental illness , 2001, BMJ : British Medical Journal.

[29]  P. L. Fevre.  Improving the Physical Health of Patients with Schizophrenia: Therapeutic Nihilism or Realism? , 2001 .

[30]  O. Benkert,et al.  Orlistat in the treatment of psychopharmacologically induced weight gain. , 2000, Journal of clinical psychopharmacology.

[31]  E. Sacchetti,et al.  H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients , 2000, Biological Psychiatry.

[32]  D. Allison,et al.  Weight gain from novel antipsychotic drugs: need for action. , 2000, General hospital psychiatry.

[33]  M. Filteau,et al.  Visual and auditory hallucinations with the association of bupropion and valproate. , 2000, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[34]  R. Aquila,et al.  Interventions for Weight Gain in Adults Treated With Novel Antipsychotics. , 2000, Primary care companion to the Journal of clinical psychiatry.

[35]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[36]  G. Blackburn,et al.  Nonpharmacologic and pharmacologic management of weight gain. , 1999, The Journal of clinical psychiatry.

[37]  S. Marder,et al.  Novel antipsychotics: comparison of weight gain liabilities. , 1999, The Journal of clinical psychiatry.

[38]  J. Birtwistle,et al.  The unhealthy lifestyle of people with schizophrenia , 1999, Psychological Medicine.

[39]  S. Svacina,et al.  Dexfenfluramine in psychotic patients. , 1998, The International journal of eating disorders.

[40]  M. Steelman.  Pharmacotherapy in the management of obesity. , 1997, JAMA.

[41]  T. Kendrick,et al.  Cardiovascular and Respiratory Risk Factors and Symptoms among General Practice Patients with Long-Term Mental Illness , 1996, British Journal of Psychiatry.

[42]  S. Merriman,et al.  Wonderful Me!: evaluation of a multidisciplinary therapy package for overweight psychiatric patients , 1995 .

[43]  L. Adams.  How exercise can help people with mental health problems. , 1995, Nursing times.

[44]  C. Morrison,et al.  Waist circumference as a measure for indicating need for weight management , 1995, BMJ.

[45]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[46]  R. Gur,et al.  Diet and Gender Moderate Clozapine-Related Weight Gain , 1994, Neuropsychopharmacology.

[47]  T. Silverstone,et al.  Prevalence of Obesity in Patients Receiving Depot Antipsychotics , 1988, British Journal of Psychiatry.

[48]  E. Goodall,et al.  A Clinical Trial of the Efficacy and Acceptability of d-Fenfluramine in the Treatment of Neuroleptic-induced Obesity , 1988, British Journal of Psychiatry.

[49]  B. Birmaher,et al.  Amantadine in the treatment of neuroendocrine side effects of neuroleptics. , 1987, Journal of clinical psychopharmacology.

[50]  A. Rotatori,et al.  Weight Loss with Psychiatric Residents in a Behavioral Self Control Program , 1980, Psychological reports.

[51]  Janis Knox.  A Study of Weight Reducing Diets in Psychiatric In-Patients , 1980, British Journal of Psychiatry.

[52]  L. Primavera,et al.  Reinforcement and Weight Loss in Schizophrenics , 1972, Psychological reports.

[53]  J. Newton,et al.  A weight-reduction program for schizophrenic patients on a token economy unit: Two case studies , 1971 .

[54]  C. H. Moore,et al.  Weight reduction in a chronic schizophrenic by means of operant conditioning procedures: a case study. , 1969, Behaviour research and therapy.

[55]  J. Bernard.  Rapid Treatment of Gross Obesity by Operant Techniques , 1968, Psychological reports.

[56]  M. Harmatz,et al.  Behavior modification of overeating in a psychiatric population. , 1968, Journal of consulting and clinical psychology.

[57]  I. Sletten,et al.  Weight reduction with chlorphenetermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy. , 1967, Current therapeutic research, clinical and experimental.

[58]  I. Sletten,et al.  Effects of caloric restriction on behavior and body weight during chlorpromazine therapy. , 1967, Diseases of the nervous system.

[59]  T. Ayllon.  INTENSIVE TREATMENT OF PSYCHOTIC BEHAVIOUR BY STIMULUS SATIATION AND FOOD REINFORCEMENT. , 1963, Behaviour research and therapy.

[60]  P. Le Fevre.  Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism? , 2001, Scottish medical journal.

[61]  Phsicians Poraduate Pess.  Metformin in Obesity Associated With Antipsychotic Drug Administration : A Pilot Study , 2001 .

[62]  G. Blackburn,et al.  Weight gain and antipsychotic medication. , 2000, The Journal of clinical psychiatry.

[63]  S. Devarajan,et al.  Clozapine weight gain, plus topiramate weight loss. , 2000, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[64]  S. Biddle,et al.  Exercise as an adjunct treatment for schizophrenia: A review of the literature , 1999 .

[65]  Treatment of Obesity in Adults.  Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. , 1998, Obesity research.

[66]  Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. , 1996, JAMA.

[67]  T. Kołakowska,et al.  An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study. , 1987, International clinical psychopharmacology.

[68]  D. Campbell,et al.  EXPERIMENTAL AND QUASI-EXPERIMENT Al DESIGNS FOR RESEARCH , 2012 .